Navigation Links
Multikine in Medical News

CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results

...oduct in the country. CEL-SCI already has existing licensing agreements for multikine with Teva Pharmaceuticals and Orient Europharma. Launch of cold 4 d...rehensive immunotherapy that targets newly diagnosed head and neck cancer. multikine is cleared by the FDA and the Canadian regulators for a global Phase III cl...

CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa

...-SCI already has existing licensing agreements for multikine with Teva Pharmaceuticals and Orient Europharma. ...or registering the product in the Territory. Once multikine has been approved, CEL-SCI will be responsible for...reement is consistent with our strategy to license multikine in the emerging markets to share the expenses of b...

CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference

...gave clearance for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de...

CEL-SCI Corporation Reports Second Quarter 2008 Financial Results

..." About Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de...

CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial

...cess, eliminating a key risk of the pivotal trial. multikine represents a completely novel medicine with blockb...reak the annual billion-dollar sales barrier'. Our multikine was one of the 10 medicines named." The article ...of the highlights include: -- FDA clearance of multikine for Phase III clinical trial in head and neck ...

CEL-SCI Corporation Releases Letter to Shareholders

... Company highlights of 2007: -- FDA clearance of multikine for Phase III clinical trial in head and neck cancer -- Raised U.S. $15 million -- multikine granted Orphan drug designation in U.S. -- Started build-out of manufacturing facility for multikine to support upcoming Phase III study and commer...

CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan

...e the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin... a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de...

Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI

... Administration (FDA) gave the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine as a neoadjuvant therapy of squamous cell carcinoma (cancer) of the head an...

New Help for Head and Neck Cancer

...oost the immune system. Patients received the multikine injections for 10 days. Two patients had a complet...e seen with the therapy. The authors conclude multikine injections may be valuable in the treatment of hea...fine the best dosage and mode of administration of multikine in patients with head and neck cancer.” ...
Multikine in Medical Technology

CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series

VIENNA, Va., July 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ), a late stage cancer immunotherapy company, announced today that Dr. Eyal Talor, CEL-SCI's Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI's Clinical Cent...

CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect

VIENNA, Va., Oct. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM ) announced today that it has entered into a Material Transfer Agreement (MTA) with the National Institutes of Health Clinical Center (NIHCC) and the laboratory of Dr. Francesco M. Marincola, M.D., to investigate the...

CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug

Biomedical Real Estate Group Backs Construction of Facility VIENNA, Va., Aug. 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM ) announced today that it has entered into an agreement with a biomedical real estate group under which CEL-SCI acquires long term use of a dedicated...

CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine

Partner to Make Direct Investment in CEL-SCI VIENNA, Va., Nov. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM ) announced today that it has expanded its exclusive licensing agreement for Multikine(R) with Orient Europharma Co., Ltd. ("Orient Europharma"), a leading pharmaceutica...

CEL-SCI Presents Long-Term Cancer Survival Data With Multikine

Multikine Improves Overall Survival by 33% 3.5 Years Post Surgery VIENNA, Va., May 21, 2007 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announced today that its cancer drug Multikine(R) was shown to significantly increase long term overall survival in a Phase II study of head and neck cancer pat...

CEL-SCI Corporation Releases Letter to Shareholders

...ncer Drug Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im...n the go-ahead for a Phase III clinical trial with multikine and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...

CEL-SCI Corporation Releases Letter to Shareholders

... Teva will participate in and pay for part of the multikine Phase III trial. We extended our multikine licensing agreement with Orient EuroPharma of Ta... our Phase III trial. multikine was named one of 10 future blockbuster drugs by M...

CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008

... 8, 2008. This dedicated facility will produce the multikine that will be used for CEL-SCI's pivotal Phase III ...ne. We are now in the home stretch. Having our own multikine dedicated manufacturing facility gives us control ... our product development." CEL-SCI is developing multikine for approval as a first line indication in head an...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

... Administration (FDA) gave the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head ...

CEL-SCI Corporation Reports First Quarter Financial Results

...ncer Drug Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...is currently building a manufacturing facility for multikine close to Baltimore, MD. Upon completion of the fac...
Multikine in Biological News

CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products

...t cold temperatures. "We developed this unique cold fill technology over the course of many years and built this new facility for our cancer drug multikine at a cost of about $22 million because we had not been able to find a company that could do a true 4 degrees Celsius cold fill for us. The best they ...
Multikine in Biological Technology

CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine

VIENNA, Va., Aug. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM ) announced today that it has entered into an exclusive licensing agreement with Teva Pharmaceutical Industries Ltd. (Teva), a leading global pharmaceutical company, under which CEL-SCI has granted Teva an exclusive...

CEL-SCI Corporation Releases Letter to Shareholders

...facturing. This facility was built to manufacture multikine for the Phase III trial and sale thereafter. Due ...ng anywhere else. This means that we can fill our multikine into vials in a completely sterile manner not only... pharmaceutical/biotechnology drug industry. multikine cancer therapy: We believe that the most cri...

CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering

...eration of our H1N1 swine flu work and the validation of our manufacturing facility for contract manufacturing services and to produce our cancer drug multikine for the planned Phase III clinical trial." The securities described above are being offered by CEL-SCI Corporation pursuant to a registration sta...

CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology

...ntigen specificity with immune response modulation. CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is multikine which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland. When used in this...

CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products

...t cold temperatures. "We developed this unique cold fill technology over the course of many years and built this new facility for our cancer drug multikine at a cost of about $22 million because we had not been able to find a company that could do a true 4 degrees Celsius cold fill for us. The best they ...

CEL-SCI Corporation Announces 2008 Financial Results

... fiscal 2008 in preparing for our pivotal trial of multikine for head and neck cancer. Expenditures for 2009 ar...sh expenditures. In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im...e the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to...

CEL-SCI Corporation Releases Letter to Shareholders

...people had expected and clearly make our non-toxic multikine cancer product even more important to develop. Se... Organization (BIO) which would help CEL-SCI bring multikine to market faster. Last, what percentage of people...er I also want to review the general status of our multikine cancer drug: 1. In the last few months we...

Updated Pictures of CEL-SCI Manufacturing Facility Available Online

...ng and FDA cleared Phase III clinical trial, as well as commercial sale, of multikine as a first line indication in treatment naive head and neck cancer patients...h other potential partners are ongoing. In Phase II clinical trials multikine was shown to be safe and well-tolerated, eliminate all of the tumor in 12% ...

CEL-SCI Takes Delivery of New Manufacturing Facility

...y, located in the Baltimore area, will produce the multikine that will be used for CEL-SCI's pivotal Phase III ...ne. We are now in the home stretch. Having our own multikine dedicated manufacturing facility gives us control ...n line for manufacturing." CEL-SCI is developing multikine for approval as a first line indication in head an...

CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results

...g facility and starting the Phase III study of our multikine cancer drug. Some additional funds were spent on o..." About Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...
Other Tags
(Date:11/27/2014)... November 27, 2014 Nearly 1,100 ... filed in a consolidated litigation now underway in ... , Documents recently updated in the Philadelphia Court ... the state proceeding, all of which involve a ... other psychiatric conditions. Many of the cases in ...
(Date:11/27/2014)... (HealthDay News) -- Most babies and young children don,t ... Food and Drug Administration says. Over-the-counter (OTC) cold ... younger than 2 because they could cause serious and ... adults average about three colds a year, but children ... parents might want to give them pain relievers, decongestants ...
(Date:11/27/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals ... eat a gluten-free diet, an expert says. Many ... potatoes and cranberry sauce -- are gluten-free, but "when ... may need to be considered," Dr. Anca Safta, director ... Wake Forest Baptist Medical Center in North Carolina, said ...
(Date:11/27/2014)... New York, NY (PRWEB) November 27, 2014 ... devoted to offering stylish, comfortable and high functioning compression socks, ... line. The newly-released socks use an innovative Gradient Pressure (TM) ... freshly oxygenated blood. , VIM & VIGR’s commitment to adding ... thought of as just functional recently caught the eye of ...
(Date:11/27/2014)... Now that Thanksgiving is finally here ... Emassagechair.com has announced its eagerly awaited, once ... , Negotiating on behalf of their customers, and drawing ... Emassagechair.com has generated significant buzz in the industry with ... yet. , Shoppers are excited for significant savings available ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4
(Date:11/10/2014)... shelves in early 2010, and people have used them ... be tossed into a washing machine without ever having ... though, has come with risks for young children. , ... found that from 2012 through 2013, U.S. poison control ... years of age swallowing, inhaling, or otherwise being exposed ...
(Date:11/6/2014)... from a team of Florida State University biologists could ... adapt to and survive environmental swings such as droughts ... issue of the journal The Plant Cell , ... and proteins) is organized in a cell and how ... turned on and others are turned off. , "If ...
(Date:11/5/2014)... in the UTSA College of Sciences, is one ... receive a two-year $300,00 National Science Foundation (NSF) ... funding supports President Obama,s BRAIN Initiative, a federal ... that will demystify complex brain processes. , ... broken into the interactions of multiple components, each ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
Other Contents